OREGON HEALTH & SCIENCE UNIVERSITY
- Unique Entity ID (UEI)
- NPSNT86JKN51
- Parent company
- OREGON HEALTH & SCIENCE UNIVERSITY (this vendor is its own parent)
- Registered address
- PORTLAND, OR, district OR-01
- Other names on record
- OHSU; OREGON GRADUATE INSTITUTE OF SCIENCE & TECHNOLOGY; OREGON HEALTH & SCIENCE UN; OREGON HEALTH & SCIENCE UNIV; OREGON HEALTH & SCIENCE UNIVER; OREGON HEALTH AND SCIENCE UNIV; OREGON HEALTH AND SCIENCE UNIVERSIT; OREGON HEALTH AND SCIENCE UNIVERSITY; OREGON HEALTH&SCIENCE UNIVERSITY; OREGON HLTH AND SCIENCE U
Dollars are contract obligations in the fiscal year, as USAspending adds them up from each award's transactions. A contract's full value can be larger and run over several years. A figure below zero is money taken back from contracts signed earlier.
Source: USAspending.gov, the Treasury’s public record of federal spending. Our copy was saved November 20, 2026.
Which agencies pay this vendor, and where the work is done
Fiscal year 2027: $2,742,192.91
| Agency | Contract dollars |
|---|---|
| Department of Veterans Affairs | $2,742,192.91 |
| District where the work is done | Contract dollars |
|---|---|
| OR-01Suzanne Bonamici | $2,742,192.91 |
Fiscal year 2026: $24,265,019.72
| Agency | Contract dollars |
|---|---|
| Department of Veterans Affairs | $19,257,447.20 |
| Department of Health and Human Services | $4,058,249.47 |
| Department of Defense | $952,668.57 |
| Department of Labor | -$3,345.52 |
| District where the work is done | Contract dollars |
|---|---|
| OR-01Suzanne Bonamici | $24,264,908.24 |
| PA-17Christopher R. Deluzio | $6,940 |
| MD-08Jamie Raskin | $0 |
| DC-98Eleanor Holmes Norton | -$3,345.52 |
| PA-12Summer L. Lee | -$3,483 |
Largest awards
The largest contract awards with activity from October 1, 2025 to September 30, 2027, by each award's total amount over its whole life. 0 rows of the answer belong to related companies and are left out.
| Award | Agency | Where the work is done | Award total | Start |
|---|---|---|---|---|
| 75N93023C00002TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS. | Department of Health and Human ServicesNational Institutes of Health | PORTLAND, OR-01 | $7,422,654 | Ends May 31, 2027 |
| 36C26026N0173DECEASED DONOR ORGAN PROCUREMENT (KIDNEYS AND LIVERS) - FUND NEXT PERIOD OF PERFORMANCE | Department of Veterans Affairs | PORTLAND, OR-01 | $5,756,966 | Ends March 31, 2027 |
| 36C26025N0112DECEASED DONOR ORGAN PROCUREMENT - BASE YEAR 1 FUNDING | Department of Veterans Affairs | PORTLAND, OR-01 | $4,757,927.85 | Ends February 28, 2026 |
| 36C26023C0002SS AFFILIATE LT GYN 1 BASE PLUS 9 OPTIONS | Department of Veterans Affairs | PORTLAND, OR-01 | $3,306,528.62 | Ends September 30, 2027 |
| 75Q80124F32025SYSTEMATIC EVIDENCE REVIEWS TO SUPPORT THE USPSTF - 2024 TOPIC BUY (GROUP B) | Department of Health and Human ServicesOffice of the Assistant Secretary for Financial Resources | PORTLAND, OR-01 | $2,510,740 | Ends August 14, 2027 |
| 36C26025P0683REFERENCE LABORATORY TESTING FOR PORTLAND VA MEDICAL CENTER | Department of Veterans Affairs | PORTLAND, OR-01 | $2,077,372.30 | Ends March 31, 2026 |
| 36C26026N0243REFERENCE LABORATORY TESTING | Department of Veterans Affairs | PORTLAND, OR-01 | $2,065,490.10 | Ends March 31, 2027 |
| 36C26026N0359REFERENCE LABORATORY SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $2,042,230.40 | Ends June 30, 2027 |
| 36C26024C0001SOLE SOURCE AFFILIATE: CARDIAC SURGERY PHYSICIAN SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $1,895,833.60 | Ends November 30, 2026 |
| 36C26026N0353LIVER RENAL TRANSPLANT AND HEPATOBILIARY SURGEONS - BASE YEAR 5 | Department of Veterans Affairs | PORTLAND, OR-01 | $1,710,458.76 | Ends July 31, 2027 |
| 36C26021C0007AFFILIATE NEUROSURGERY MD SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $1,705,281.92 | Ends January 31, 2027 |
| 36C26025N0316LIVER RENAL TRANSPLANT AND HEPATOBILIARY SURGEONS - FUND BASE YEAR 4 | Department of Veterans Affairs | PORTLAND, OR-01 | $1,701,979.42 | Ends July 31, 2026 |
| 36C26025P0894REFERENCE LABORATORY TESTING FOR VA PORTLAND HEALTH CARE SYSTEM | Department of Veterans Affairs | PORTLAND, OR-01 | $1,684,222.65 | Ends June 30, 2026 |
| 36C26024P0508REFERENCE LABORATORY TESTING FOR THE VA PORTLAND HEALTH CARE SYSTEM | Department of Veterans Affairs | PORTLAND, OR-01 | $1,643,458.96 | Ends April 30, 2025 |
| 36C26022C0004SOLE SOURCE AFFILIATE- ORTHOPEDIC PHYSICIAN SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $1,432,510.23 | Ends June 30, 2027 |
| 36C26025N0018AFFILIATE LT INTERVENTIONAL RADIOLOGY PHYSICIAN SERVICES- 52.217-8 OPTION TO EXTEND SERVICES, TO: IDIQ OPT PERIOD 1 YR 1 | Department of Veterans Affairs | PORTLAND, OR-01 | $1,425,507.02 | Ends September 30, 2025 |
| 36C26025P0022REFERENCE LAB TESTING F/VA PORTLAND HEALTH CARE SYSTEM. | Department of Veterans Affairs | PORTLAND, OR-01 | $1,386,363.52 | Ends August 31, 2025 |
| 36C26026N0034AFFILIATE LT INTERVENTIONAL RADIOLOGY PHYSICIAN SERVICES- TO: OPTION PERIOD 1, YEAR 2 | Department of Veterans Affairs | PORTLAND, OR-01 | $1,347,161.11 | Ends September 30, 2026 |
| 36C26025C0015SOLE SOURCE AFFILIATE NEURORADIOLOGY PHYSICIAN SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $1,132,255.19 | Ends March 31, 2026 |
| 36C26022C0016EDUCATIONAL COSTS REIMBURSEMENT - SOLE SOURCE AFFILIATE | Department of Veterans Affairs | PORTLAND, OR-01 | $1,106,033.75 | Ends July 31, 2027 |
| 36C26027N0024SSA INTERVENTIONAL RADIOLOGY PHYSICIAN SERVICES - OPTION PERIOD ONE YEAR 3 POP: 10/1/2026-9/30/2027 648C75035 | Department of Veterans Affairs | PORTLAND, OR-01 | $997,971.83 | Ends September 30, 2027 |
| 36C26024P0174REFERRAL LABORATORY TESTING FOR THE VA PORTLAND HEALTH CARE SYSTEM | Department of Veterans Affairs | PORTLAND, OR-01 | $973,678.50 | Ends September 30, 2024 |
| 36C26023C0004SOLE SOURCE AFFILIATE OPHTHALMOLOGY PHYSICIAN SERVICES 1 BASE PLUS 4 ONE-YEAR OPTIONS | Department of Veterans Affairs | PORTLAND, OR-01 | $887,510.20 | Ends February 28, 2027 |
| 36C26022C0008SOLE SOURCE AFFILIATE DERMATOLOGY PHYSICIAN SERVICES PORTLAND VA MEDICAL CENTER | Department of Veterans Affairs | PORTLAND, OR-01 | $794,557.03 | Ends May 31, 2027 |
| 36C26023C0001SOLE SOURCE AFFILIATE: THORACIC SURGERY PHYSICIAN SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $745,409.40 | Ends November 30, 2027 |
| 36C26021C0011LT AFFILIATE OHSU VASCULAR SURGERY PHYSICIAN SERVICE 1 BASE PLUS SIX ONE-YEAR OPTIONS | Department of Veterans Affairs | PORTLAND, OR-01 | $728,040.64 | Ends May 31, 2027 |
| 75N94025F00002NICHD:R&D:CENTRAL LABORATORY FOR A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION:NON-SEVERABLE | Department of Health and Human ServicesNational Institutes of Health | PORTLAND, OR-01 | $720,543 | Ends December 31, 2027 |
| 75N94018F00008IGF::OT::IGF PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION | Department of Health and Human ServicesNational Institutes of Health | PORTLAND, OR-01 | $632,381.06 | Ends July 14, 2026 |
| 36C24E26N0104MACHINE LEARNING & DATA EXTRACTION WITH BIOSTATISTICAL SUPPORT | Department of Veterans Affairs | PORTLAND, OR-01 | $620,173 | Ends September 15, 2027 |
| 36C26021C0009SSA UROLOGY PHYSICIANS PORTLAND VA | Department of Veterans Affairs | PORTLAND, OR-01 | $616,547.67 | Ends May 31, 2026 |
| 75N94021F00001CENTRAL LABORATORY FOR PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION | Department of Health and Human ServicesNational Institutes of Health | PORTLAND, OR-01 | $557,412 | Ends July 14, 2026 |
| 75F40121C00120HYPOTHESIZE THE CONCEPTUAL FRAMEWORK TO IDENTIFY THE RELEVANT CONCEPTS, DRAFT INSTRUMENT, AND THE CONCEPTUAL FRAMEWORK AND ASSESS OTHER MEASUREMENT PROPERTIES. | Department of Health and Human ServicesFood and Drug Administration | PORTLAND, OR-01 | $546,710.08 | Ends September 29, 2024 |
| 75N94025F00001NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE | Department of Health and Human ServicesNational Institutes of Health | PORTLAND, OR-01 | $543,456.76 | Ends December 31, 2027 |
| 36C24E21C0001RESEARCH SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $541,336.86 | Ends June 30, 2024 |
| 36C26026C0002SOLE SOURCE AFFILIATE: RADIATION ONCOLOGY PHYSICIAN SERVICES | Department of Veterans Affairs | PORTLAND, OR-01 | $430,934.40 | Ends November 30, 2027 |
| 36C26026N0191SOLE SOURCE AFFILIATE PERFUSIONIST SERVICES - EXERCISE OY4 | Department of Veterans Affairs | PORTLAND, OR-01 | $384,000 | Ends March 31, 2027 |
| 75Q80120F32005METHODS AND DISSEMINATION: COLLABORATION TO IMPROVE VALIDITY, CONSISTENCY, AND UTILITY OF SYSTEMATIC REVIEWS | Department of Health and Human ServicesAgency for Healthcare Research and Quality | ROCKVILLE, MD-08 | $350,000 | Ends December 27, 2025 |
| 36C24E26N0280RESEARCH SERVICES FOR DATA ENGINEERING, VISUALIZATIONS EXPERTISE, AND COMPLEX ALGORITHM AND CODE PRODUCTION | Department of Veterans Affairs | PORTLAND, OR-01 | $339,894 | Ends September 28, 2027 |
| 36C26025N0193SOLE SOURCE AFFILIATE PERFUSIONIST SERVICES - EXERCISE OY3 | Department of Veterans Affairs | PORTLAND, OR-01 | $296,580 | Ends March 31, 2026 |
| 36C26024N0169SOLE SOURCE AFFILIATE PERFUSIONIST SERVICES - EXERCISE OPTION YEAR 2 | Department of Veterans Affairs | PORTLAND, OR-01 | $293,790 | Ends March 31, 2025 |
Subcontracts it reported
A prime contractor reports the subcontracts it gives under an award (first-tier subawards). These are the largest it reported under its three largest awards, from every year of each award.
Under award 75N93023C00002
| Subcontractor | What it is for, as reported | Amount | Date |
|---|---|---|---|
| SRI INTERNATIONAL | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $1,765,744 | |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $811,407 | |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $811,407 | |
| THE REGENTS OF THE UNIVERSITY OF COLORADO | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $447,867 | |
| SRI INTERNATIONAL | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $390,231 | |
| SOUTHERN RESEARCH INSTITUTE | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $345,915 | |
| SOUTHERN RESEARCH INSTITUTE | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $345,915 | |
| ELEMENT MATERIALS TECHNOLOGY SANTA CLARA INC. | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $187,000 | |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | $18,000 |
Lobbying reports and campaign receipts that name this vendor
No lobbying report, organization page or FEC receipt in our saved records has this vendor’s name or its parent company’s name.
A name is matched only when it is the same name under the exact-name rule: letters and numbers alike, "&" read as "and", a leading "the" and one closing legal form (Inc, LLC, Corp, Corporation, Co, LP, LLP) set aside. A near name is never a match. Each match says which name matched.